Welcome to Markets Desk, your midday read on what's moving markets and the stories behind the numbers.
Alnylam Pharmaceuticals is in focus after presenting new clinical data at the European Society of Cardiology Congress validating AMVUTTRA for transthyretin amyloidosis, a rare and serious heart condition. The company also provided updates on zilebesiran, its experimental hypertension therapy, reinforcing its pipeline depth and keeping ALNY on the radar of biotech investors watching the RNAi space closely.
Shifting to retail, pressure is mounting on Target's leadership after its annual shareholder meeting revealed nearly thirteen percent of investors voted against Executive Chair Brian Cornell's reelection. A separate proposal calling for an independent board chair drew nearly forty percent support, a striking signal that institutional patience with Target's strategic direction is wearing thin after a prolonged stretch of consumer and investor alienation.
And in the energy and infrastructure space, Pennsylvania is grappling with a structural tension as surging data center demand drives electricity costs higher, while state regulations prevent utilities from building the new generation capacity needed to keep pace. It is a microcosm of a national challenge — artificial intelligence infrastructure growth colliding directly with legacy utility frameworks that were never designed for this kind of load.
That's the tape. Markets Desk, signing off the floor.
